Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gout is the new black but will Ardea appease AstraZeneca investors?

This article was originally published in Scrip

Executive Summary

AstraZeneca's planned $1.26 billion acquisition of Ardea Biosciences, following hot on the heels of Takeda's announced purchase of URL Pharma, has highlighted the growing interest in the gout market. Once seen as an unpromising area dominated by decades-old treatments, big pharma had previously shown little interest in developing new products for the condition. However, current treatments leave many sufferers in need of better options, and big pharma, having to work harder for its money now that the days of sitting back and raking in the cash on one or two major patented primary care products, appears to be waking up to the fact that gout might be useful to it after all.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts